[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613032":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":34,"locations":40,"responsibleParty":59,"collaborators":25,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":68,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":25,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":43,"whyStopped":25,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Lahore General Hospital","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group mTX","ACTIVE_COMPARATOR","Methotrexate is a modified antirheumatic drug work by inhibiting dihydrofolate reductase",[13],"Drug: Methotrexate",{"label":15,"type":10,"description":16,"interventionNames":17},"Tofacitinib","Tofacitinib is janus kinase inhibitor and had a role in treatment of psoriasis and psoriatic arthritis",[18],"Drug: Tofacitinib",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Methotrexate","Methotrexate is an antifolate drug work by inhibiting enzyme dihydrofolate reductase and inhibit cell proliferation and play a role in psoriasis treatment",[9],null,{"type":21,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Tofacitinib is janus kinase inhibitor and have role in psoriasis",[15],[30],{"name":31,"affiliation":32,"role":33},"Maryam Fatima","Lahore General Hospital, Lahore","PRINCIPAL_INVESTIGATOR",[35],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},"Maryam Fatima, Mbbs","CONTACT","03361409014","maryamfatima726@yahoo.com",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":25,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Lahore general hospital","RECRUITING","Lahore","Punjab Province","Pakistan","PK",{"type":49,"coordinates":50},"Point",[51,52],74.35071,31.558,{"lat":52,"lon":51},[55],{"name":56,"role":37,"phone":57,"phoneExt":25,"email":58},"Dr Ayesha Wahid, Fcps","+92 323 4822177","zaeemakanwal@hotmail.com",{"type":33,"investigatorFullName":31,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Principal Investigator","100613032","early-phase-1-comparison-between-oral-methotrexate-and-tofacitinib-in-chronic-plaque-psoriasis-100613032",false,"NCT07261306","Comparison Between Oral Methotrexate and Tofacitinib in Chronic Plaque Psoriasis","MTX","Inclusion Criteria:\n\n* Patients aged 18- 70 years of either gender.\n* Only patients with Psoriasis Area and Severity Index (PASI) score of 10 or above, and\u002For Body Surface Area (BSA) involvement of 10% or more, will be included.\n* Duration of plaque psoriasis for at least 6 months prior to the study.\n* Psoriasis that has not shown adequate response to topical therapies\n\nExclusion Criteria:\n\n* Individuals with other forms of psoriasis or other significant dermatological conditions that might interfere with the assessment of psoriasis.\n* Participants currently receiving systemic corticosteroids, biologics, or any other immunosuppressive agents within 4 weeks prior to the start of the study will be excluded.\n* Known hypersensitivity or contraindications to either methotrexate or tofacitinib.\n* History of significant liver, kidney, hematologic\u002Fbleeding disorder, gastrointestinal\u002Facid peptic disease, or immune system disorders.and any history of tuberculosis and malignancy.\n* Pregnant or lactating women will not be eligible for the study.",true,"ALL","18 Years","70 Years",{"count":73,"type":74},75,"ESTIMATED","INTERVENTIONAL",[77],"EARLY_PHASE1","Psoriasis is a chronic inflammatory dermatoses which include well demarcated scaly erythematous plaques on whole body including scalp role of methotrexate vs tofacitinib is compared in this study",[80],"Psoriasis",[82,15],"MtX","2025-11-21",{"date":85,"type":86},"2025-12-03","ACTUAL",{"date":88,"type":86},"2025-08-29",{"date":90,"type":74},"2025-12-25",{"name":5,"class":6},1]